# US 4,536,387 A · Anti-cancer device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,536,387 A
- Document ID: US4536387A
- Status: Granted
- Kind: A
- Application number: 06/466,190
- Filed: 1983-02-14
- Granted: 1985-08-20
- Earliest claimed: 1982-02-12
- Assignees: Unitika Ltd.
- Inventors: Izumi Sakamoto; Kunihiko Takagi
- Web page: https://patentgrep.com/patent/US4536387A

## CPC

- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An anti-cancer device having an anti-cancer drug and a blood coagulation factor fixed to a structure. This anti-cancer device is used in transcatheter arterial embolization and needle therapy with advantage and slowly releases the anti-cancer drug over an extended period by staying in the cancer tissue and its nearby area.

## Claims

### Claim 1

A method of transcatheter arterial embolization and needle therapy comprising injecting a patient with composition useful for transcatheter arterial embolization and needle therapy comprising:
(a) a polymer, wherein said polymer has fixed thereto;
(b) an anti-cancer drug; and
(c) a blood coagulation factor, wherein said anti-cancer drug and said blood coagulation factor are fixed to said polymer so as to be capable of sustained release from the polymer at the site of injection.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a synthetic polymer.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein said synthetic polymer is silicone.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein said polymer is selected from the group consisting of cellulosic material, cellulosic material derivative and regenerated cellulose.

### Claim 5 (depends on 4)

The method as claimed in claim 4, wherein said cellulosic material derivative is ethyl cellulose.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein said polymer is bioabsorbable material.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein said bioabsorbable material is polysaccharide.

### Claim 8 (depends on 7)

The method as claimed in claim 7, wherein said polysaccharide is amylose.

### Claim 9 (depends on 7)

The method as claimed in claim 7, wherein said polysaccharide is oxidized cellulose.

### Claim 10 (depends on 7)

The method as claimed in claim 7, wherein said polysaccharide is chitin.

### Claim 11 (depends on 6)

The method as claimed in claim 6, wherein said bioabsorbable material is collagen.

### Claim 12 (depends on 6)

The method as claimed in claim 6, wherein said bioabsorbable material is gelatin.

### Claim 13 (depends on 6)

The method as claimed in claim 6, wherein said bioabsorbable material is polyamino acid.

### Claim 14 (depends on 13)

The method as claimed in claim 13, wherein said polyamino acid is polyglycolic acid.

### Claim 15 (depends on 13)

The method as claimed in claim 13, wherein said polyamino acid is polylactic acid.

### Claim 16 (depends on 1)

The method as claimed in claim 1, wherein the polymer is in the form of a fibrous assembly.

### Claim 17 (depends on 16)

The method as claimed in claim 16, wherein said fibrous assembly is an assembly of oxidized cellulose fiber.

### Claim 18 (depends on 16)

The method as claimed in claim 16, wherein said fibrous assembly is an assembly of gelatin fiber.

### Claim 19 (depends on 16)

The method as claimed in claim 16, wherein said fibrous assembly is an assembly of chitin fiber.

### Claim 20 (depends on 1)

The method as claimed in claim 1, wherein said polymer is in the form of a sponge.

### Claim 21 (depends on 20)

The method as claimed in claim 20, wherein said sponge is oxidized cellulose sponge.

### Claim 22 (depends on 20)

The method as claimed in claim 20, wherein said sponge is gelatin sponge.

### Claim 23 (depends on 20)

The method as claimed in claim 20, wherein said sponge is chitin sponge.

### Claim 24 (depends on 1)

The method as claimed in claim 1, wherein said polymer is in the form of a powder.

### Claim 25 (depends on 24)

The method as claimed in claim 24, wherein said powder is oxidized cellulose powder.

### Claim 26 (depends on 24)

The method as claimed in claim 24, wherein said powder is gelatin powder.

### Claim 27 (depends on 24)

The method as claimed in claim 24, wherein said powder is chitin powder.

### Claim 28 (depends on 1)

The method as claimed in claim 1, wherein said polymer is in the form of a monofilament.

### Claim 29 (depends on 1)

The method as claimed in claim 1, wherein said polymer is in the form of a film.

### Claim 30 (depends on 1)

The method as claimed in claim 1, wherein said polymer is in the form of a microcapsule.

### Claim 31 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is an alkylating agent.

### Claim 32 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is a combination of cyclophosphamide, 5-fluorouracil and mitomycin.

### Claim 33 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is a combination of cyclophosphamide, 5-fluorouracil and bleomycin.

### Claim 34 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is bleomycin.

### Claim 35 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is mitomycin C.

### Claim 36 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is adriamycin.

### Claim 37 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug is 5-fluorouracil.

### Claim 38 (depends on 1)

The method as claimed in claim 1, wherein said blood coagulation factor is Factor XIII.

### Claim 39 (depends on 1)

The method as claimed in claim 1, wherein said blood coagulation factor is thrombin.

### Claim 40 (depends on 1)

The method as claimed in claim 1, wherein said blood coagulation factor is a combination of Factor XIII and thrombin.

### Claim 41 (depends on 1)

The method as claimed in claim 1, wherein said anti-cancer drug and blood coagulation factor are fixed to the polymer by covalently bonding to the polymer.

### Claim 42 (depends on 1, 6, 16, 20, 24, 28, 29, 30)

The method as claimed in claims 1, 6, 16, 20, 24, 28, 29 or 30, wherein said anti-cancer drug and blood coagulation factor are fixed to the said polymer by ionically bonding to said polymer.

### Claim 43 (depends on 1, 6, 16, 20, 24, 28, 29, 30)

The method as claimed in claims 1, 6, 16, 20, 24, 28, 29 or 30, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer by adsorption.

### Claim 44 (depends on 1, 6, 16, 20, 24, 28, 29, 30)

The method as claimed in claims 1, 6, 16, 20, 24, 28, 29 or 30, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer for entrapping.

### Claim 45 (depends on 1)

The method as claimed in claim 1, wherein calcium ion is additionally fixed to said polymer.

### Claim 46 (depends on 1)

The method as claimed in claim 1, wherein a pharmaceutical is additionally fixed to said polymer.

### Claim 47 (depends on 46)

The method as claimed in claim 46, wherein said pharmaceutical is selected from the group consisting of protease inhibitors, plasma proteins, fibronectin, antiboitics, antivirals, sulfaniamides and anti-infectives.

### Claim 48 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a bioabsorbable polymer and wherein said polymer is in the form of a fibrous assembly.

### Claim 49 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a sponge.

### Claim 50 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a powder.

### Claim 51 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a monofilament.

### Claim 52 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a film.

### Claim 53 (depends on 1)

The method as claimed in claim 1, wherein said polymer is a bioabsorbable material and wherein said polymer is in the form of a microcapsule.

### Claim 54 (depends on 1)

The method as claimed in claim 1, wherein said polymer is gelatin powder, said anti-cancer drug, and said blood coagulation factor are fixed to said polymer by ionic bonding, entrapping and adsorption, said anti-cancer drug is mitomycin C and wherein said blood coagulation factor is a combination of Factor XIII and thrombin.
